Personalized Thera(g)nostic Approach in Patients with Pheochromocytoma and Paraganglioma: 131I-mIBG and/or Peptide Receptor Radionuclide Therapy

被引：0
|
作者：
Svirydenka, H. [1 ]
Nilica, B. [1 ]
Mair, C. [1 ]
Rossetti, L. [1 ]
Kroiss, A. [1 ]
Di Santo, G. [1 ]
Buxbaum, S. [1 ]
Decristoforo, C. [1 ]
Uprimny, C. [1 ]
Gabriel, M. [1 ]
Virgolini, I. [1 ]
机构：
[1] Univ Klin Nukl Med, Innsbruck, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-563
引用
收藏
页码：S278 / S278
页数：1
相关论文
共 50 条
  • [31] 131I-MIBG therapy with WT-1 peptide for refractory neuroblastoma
    Sugiyama, Minako
    Seigo, Kinuya
    Hosoya, Yosuke
    Iguchi, Akihiro
    Manabe, Atsushi
    PEDIATRICS INTERNATIONAL, 2020, 62 (06) : 746 - 747
  • [32] Evaluating the diagnostic efficacy of whole-body MRI versus 123I-mIBG/131I-mIBG imaging in metastatic pheochromocytoma and paraganglioma
    Mori, Hiroshi
    Wakabayashi, Hiroshi
    Saito, Shintaro
    Nakajima, Kenichi
    Yoshida, Kotaro
    Hiromasa, Tomo
    Kinuya, Seigo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [33] 131I-MIBG therapy: Dosimetry estimations in neuroendocrine patients.
    Castellani, M. R.
    Chiesa, C.
    Luksch, R.
    Aliberti, A.
    Maccauro, M.
    Seregni, E.
    Bombardieri, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S317 - S317
  • [34] Peptide receptor radionuclide therapy (PRRT) for progressive, somatostatin receptor positive pheochromocytoma/paraganglioma
    Prasad, V.
    Zachert, C.
    Schuchardt, C.
    Wortmann, R.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S351 - S351
  • [35] 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma: An individualised approach
    George, S.
    Kirk, S. J.
    Lancaster, D.
    Vaidya, S. J.
    Mandeville, H.
    Saran, F.
    Chittenden, S.
    Pearson, A. D. J.
    Du, Y.
    Flux, G. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S352 - S352
  • [36] Repeated I-131-MIBG Therapy in Patients with Malignant Pheochromocytoma
    Lam, M. G. E. H.
    Lips, C. J. M.
    Jager, P. L.
    Lentjes, E. G. W. M.
    van Rijk, P. P.
    de Klerk, J. M. H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S201 - S201
  • [37] Whole-Body Dosimetry for Individualized Treatment Planning of 131I-MIBG Radionuclide Therapy for Neuroblastoma
    Buckley, Susan E.
    Chittenden, Sarah J.
    Saran, Frank H.
    Meller, Simon T.
    Flux, Glenn D.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (09) : 1518 - 1524
  • [38] High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
    Jha, Abhishek
    Taieb, David
    Carrasquillo, Jorge A.
    Pryma, Daniel A.
    Patel, Mayank
    Millo, Corina
    de Herder, Wouter W.
    Del Rivero, Jaydira
    Crona, Joakim
    Shulkin, Barry L.
    Virgolini, Irene
    Chen, Alice P.
    Mittal, Bhagwant R.
    Basu, Sandip
    Dillon, Joseph S.
    Hope, Thomas A.
    Aparici, Carina Mari
    Iagaru, Andrei H.
    Hicks, Rodney J.
    Avram, Anca M.
    Strosberg, Jonathan R.
    Civelek, Ali Cahid
    Lin, Frank I.
    Pandit-Taskar, Neeta
    Pacak, Karel
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 2989 - 2995
  • [39] 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome
    Pathirana, AA
    Vinjamuri, S
    Byrne, C
    Ghaneh, P
    Vora, J
    Poston, GJ
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (04): : 404 - 408
  • [40] Successful Treatment of Coexisting Paraganglioma of the Retroperitoneum and Urinary Bladder by Intermediate-Dose 131I-MIBG Therapy
    Cai, Yi
    Li, Han-Zhong
    Zhang, Yu-Shi
    MEDICINE, 2015, 94 (41)
12345